These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

491 related items for PubMed ID: 16724058

  • 1. Mechanisms of drug inhibition of signalling molecules.
    Sebolt-Leopold JS, English JM.
    Nature; 2006 May 25; 441(7092):457-62. PubMed ID: 16724058
    [Abstract] [Full Text] [Related]

  • 2. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S, Djelloul S, Raymond E.
    Semin Oncol; 2006 Aug 25; 33(4):407-20. PubMed ID: 16890796
    [Abstract] [Full Text] [Related]

  • 3. Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies.
    Rowinsky EK.
    J Clin Oncol; 2003 May 15; 21(10 Suppl):175s-186s. PubMed ID: 12743132
    [Abstract] [Full Text] [Related]

  • 4. Targeting cancer with phosphodiesterase inhibitors.
    Savai R, Pullamsetti SS, Banat GA, Weissmann N, Ghofrani HA, Grimminger F, Schermuly RT.
    Expert Opin Investig Drugs; 2010 Jan 15; 19(1):117-31. PubMed ID: 20001559
    [Abstract] [Full Text] [Related]

  • 5. Preclinical and clinical development of novel agents that target the protein kinase C family.
    Serova M, Ghoul A, Benhadji KA, Cvitkovic E, Faivre S, Calvo F, Lokiec F, Raymond E.
    Semin Oncol; 2006 Aug 15; 33(4):466-78. PubMed ID: 16890801
    [Abstract] [Full Text] [Related]

  • 6. The insulin-like growth factor 1 receptor in cancer: old focus, new future.
    Hartog H, Wesseling J, Boezen HM, van der Graaf WT.
    Eur J Cancer; 2007 Sep 15; 43(13):1895-904. PubMed ID: 17624760
    [Abstract] [Full Text] [Related]

  • 7. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
    Gollob JA, Wilhelm S, Carter C, Kelley SL.
    Semin Oncol; 2006 Aug 15; 33(4):392-406. PubMed ID: 16890795
    [Abstract] [Full Text] [Related]

  • 8. Targeting cancer with small-molecular-weight kinase inhibitors.
    Fabbro D, Cowan-Jacob SW, Möbitz H, Martiny-Baron G.
    Methods Mol Biol; 2012 Aug 15; 795():1-34. PubMed ID: 21960212
    [Abstract] [Full Text] [Related]

  • 9. PI3K and mTOR inhibitors: a new generation of targeted anticancer agents.
    Brachmann S, Fritsch C, Maira SM, García-Echeverría C.
    Curr Opin Cell Biol; 2009 Apr 15; 21(2):194-8. PubMed ID: 19201591
    [Abstract] [Full Text] [Related]

  • 10. Targeting protein kinases in cancer therapy: a success?
    Pearson MA, Fabbro D.
    Expert Rev Anticancer Ther; 2004 Dec 15; 4(6):1113-24. PubMed ID: 15606337
    [Abstract] [Full Text] [Related]

  • 11. Targeted therapies: a new generation of cancer treatments.
    Gerber DE.
    Am Fam Physician; 2008 Feb 01; 77(3):311-9. PubMed ID: 18297955
    [Abstract] [Full Text] [Related]

  • 12. Targeted cancer therapy: promise and reality.
    Klein S, Levitzki A.
    Adv Cancer Res; 2007 Feb 01; 97():295-319. PubMed ID: 17419951
    [Abstract] [Full Text] [Related]

  • 13. Molecular mechanisms of signal transduction: epidermal growth factor receptor family, vascular endothelial growth factor family, Kit, platelet-derived growth factor receptor, Ras.
    Erman M.
    J BUON; 2007 Sep 01; 12 Suppl 1():S83-94. PubMed ID: 17935283
    [Abstract] [Full Text] [Related]

  • 14. Targeted cancer therapy.
    Sawyers C.
    Nature; 2004 Nov 18; 432(7015):294-7. PubMed ID: 15549090
    [Abstract] [Full Text] [Related]

  • 15. Targeting transcription factors for cancer therapy.
    Frank DA.
    IDrugs; 2009 Jan 18; 12(1):29-33. PubMed ID: 19127502
    [Abstract] [Full Text] [Related]

  • 16. Targeting RAS signalling pathways in cancer therapy.
    Downward J.
    Nat Rev Cancer; 2003 Jan 18; 3(1):11-22. PubMed ID: 12509763
    [Abstract] [Full Text] [Related]

  • 17. Targeting mTOR for cancer treatment.
    Rubio-Viqueira B, Hidalgo M.
    Curr Opin Investig Drugs; 2006 Jun 18; 7(6):501-12. PubMed ID: 16784020
    [Abstract] [Full Text] [Related]

  • 18. DNA structure and integrity checkpoints during the cell cycle and their role in drug targeting and sensitivity of tumor cells to anticancer treatment.
    Skladanowski A, Bozko P, Sabisz M.
    Chem Rev; 2009 Jul 18; 109(7):2951-73. PubMed ID: 19522503
    [No Abstract] [Full Text] [Related]

  • 19. Small-molecule kinase-inhibitor target assessment.
    Kung C, Shokat KM.
    Chembiochem; 2005 Mar 18; 6(3):523-6. PubMed ID: 15696508
    [Abstract] [Full Text] [Related]

  • 20. Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology.
    McDermott U, Settleman J.
    J Clin Oncol; 2009 Nov 20; 27(33):5650-9. PubMed ID: 19858389
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.